CStone raises $150M series A

Chinese newco CStone Pharmaceuticals Co. Ltd. raised $150 million in a series A round from Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures.

CStone, which has offices in Shanghai and Suzhou, said its primary therapeutic focus is immuno-oncology but has not disclosed details of its development candidates. CStone's pipeline also includes undisclosed preclinical candidates in cardiovascular, hematology and autoimmune diseases, including rheumatoid arthritis. ...